

# Ming-Zhi Zhang

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7628698/ming-zhi-zhang-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

207 papers	2,382 citations	23 h-index	39 g-index
228 ext. papers	3,204 ext. citations	4.7 avg, IF	5.3 L-index

#	Paper	IF	Citations
207	Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-6	1.9	
206	Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.. <i>Investigational New Drugs</i> , <b>2022</b> , 1	4.3	1
205	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study.. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2022</b> , 38, 42-50	0.7	1
204	IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.. <i>Investigational New Drugs</i> , <b>2022</b> , 1	4.3	2
203	CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes.. <i>Leukemia Research</i> , <b>2022</b> , 117, 106840	2.7	0
202	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 846357	5.7	
201	The Effect of Chronic Rhinosinusitis on the Staging and Prognosis of Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Retrospective Analysis.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 878559	5.3	
200	A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents.. <i>Scientific Reports</i> , <b>2022</b> , 12, 7118	4.9	
199	Hsa_circ_0023984 Regulates Cell Proliferation, Migration, and Invasion in Esophageal Squamous Cancer via Regulating miR-1294/PI3K/Akt/c-Myc Pathway.. <i>Applied Biochemistry and Biotechnology</i> , <b>2022</b> , 1	3.2	0
198	CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3. <i>Cancer Cell International</i> , <b>2021</b> , 21, 594	6.4	1
197	The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells. <i>Blood</i> , <b>2021</b> , 138, 3830-3830	2.2	1
196	Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study. <i>Blood</i> , <b>2021</b> , 138, 2480-2480	2.2	
195	Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase II Trial. <i>Blood</i> , <b>2021</b> , 138, 1368-1368	2.2	1
194	Fotemustine-Containing Regimens Versus Regimens Based on High-Dose Methotrexate in Newly Diagnosed PCNSL. <i>Blood</i> , <b>2021</b> , 138, 4559-4559	2.2	
193	Analysis of the Tumor Microenvironment By Quantitative Immunohistochemistry Reveals Novel Predictors in Classic Hodgkin Lymphoma Treated with Anti-PD1 Therapy. <i>Blood</i> , <b>2021</b> , 138, 4530-4530	2.2	
192	Integrating Circulating Tumor DNA Features and Plasma Protein Markers to Detected Early Lymphoid Neoplasm. <i>Blood</i> , <b>2021</b> , 138, 4489-4489	2.2	
191	The Synergistic Anticancer Effect of a Combination of Chidamide and Etoposide Against NK/T Cell Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 3987-3987	2.2	1

190	A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma. <i>Blood</i> , <b>2021</b> , 138, 3829-3829	2.2	4
189	Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells. <i>Cancer Cell International</i> , <b>2021</b> , 21, 191	6.4	9
188	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1509-1516	3	2
187	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. <i>Neoplasia</i> , <b>2021</b> , 23, 361-374	6.4	4
186	Identification of Prognostic Related Genes of Tumor Microenvironment Derived From Esophageal Cancer Patients. <i>Pathology and Oncology Research</i> , <b>2021</b> , 27, 589662	2.6	1
185	Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate. <i>Scientific Reports</i> , <b>2021</b> , 11, 11220	4.9	2
184	Hydroa vacciniforme-like lymphoproliferative disorder: A clinicopathological, immunohistochemical, and prognostic study of 24 cases in China. <i>Journal of Dermatology</i> , <b>2021</b> , 48, 1315-1326	1.6	1
183	Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. <i>Chinese Medical Journal</i> , <b>2021</b> , 134, 1299-1309	2.9	2
182	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 687374	5.3	2
181	Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system. <i>Hematological Oncology</i> , <b>2021</b> ,	1.3	1
180	Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 663961	5.3	1
179	A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. <i>Chinese Medical Journal</i> , <b>2021</b> , 134, 1584-1592	2.9	0
178	LncRNA MEG3 regulates breast cancer proliferation and apoptosis through miR-141-3p/RBMS3 axis. <i>Genomics</i> , <b>2021</b> , 113, 1689-1704	4.3	4
177	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. <i>Cancer Research and Treatment</i> , <b>2021</b> , 53, 837-846	5.2	5
176	MYD88 L265P elicits mutation-specific ubiquitination to drive NF- $\kappa$ B activation and lymphomagenesis. <i>Blood</i> , <b>2021</b> , 137, 1615-1627	2.2	5
175	Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 1470-1477	7.5	3
174	DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 405-411	4.9	1
173	Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p/GRB14/PDGFR $\beta$ pathway as a key regulatory mechanism in Glioblastoma progression and radioresistance: Functional validation and clinical theranostic significance. <i>International Journal of Biological Sciences</i> , <b>2021</b> , 17, 1064-1078	11.2	5

172	Emerging Roles for the Gut Microbiome in Lymphoid Neoplasms. <i>Clinical Medicine Insights: Oncology</i> , <b>2021</b> , 15, 11795549211024197	1.8	1
171	Updating targets for natural killer/T-cell lymphoma immunotherapy. <i>Cancer Biology and Medicine</i> , <b>2021</b> , 18, 52-62	5.2	1
170	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplorer-002). <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 12	22.4	10
169	New prognostic models for extranodal natural killer T-cell lymphoma, nasal-type using Cox regression and machine learning.. <i>Translational Cancer Research</i> , <b>2021</b> , 10, 613-626	0.3	0
168	Significant Diagnostic and Prognostic Value of FLAD1 and Related MicroRNAs in Breast Cancer after a Pan-Cancer Analysis. <i>Disease Markers</i> , <b>2021</b> , 2021, 6962526	3.2	1
167	Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF- $\kappa$ B/p65 pathway. <i>Environmental Toxicology and Pharmacology</i> , <b>2021</b> , 85, 103639	5.8	0
166	Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. <i>European Journal of Cancer</i> , <b>2021</b> ,	7.5	4
165	Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2021</b> , 11, 686595	5.9	1
164	GNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/ $\beta$ -catenin signaling pathway. <i>Archives of Biochemistry and Biophysics</i> , <b>2021</b> , 710, 108998	4.1	2
163	Suppression of latent transforming growth factor- $\beta$ binding protein 1 (LTBP1) inhibits natural killer/ T cell lymphoma progression by inactivating the TGF- $\beta$ /Smad and p38 pathways. <i>Experimental Cell Research</i> , <b>2021</b> , 407, 112790	4.2	3
162	Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. <i>Cancer Medicine</i> , <b>2021</b> , 10, 999-1011	4.8	10
161	Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.. <i>American Journal of Translational Research (discontinued)</i> , <b>2021</b> , 13, 12206-12216	3	
160	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 148	22.4	12
159	CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 488	5.3	4
158	Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1847-1853	4.3	3
157	Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) CHOP in newly diagnosed peripheral T-cell lymphoma patients. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920923829	5.4	3
156	Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. <i>Clinical Immunology</i> , <b>2020</b> , 214, 108382	9	11
155	A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. <i>Leukemia</i> , <b>2020</b> , 34, 2243-2248	10.7	14

154	Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. <i>Drug Design, Development and Therapy</i> , <b>2020</b> , 14, 275-284	4.4	5
153	Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. <i>Haematologica</i> , <b>2020</b> , 105, e107-e110	4.6	4
152	Activating NOTCH1 Mutations Alter T-ALL Chemosensitivity By PREX2-AKT Pathway. <i>Blood</i> , <b>2020</b> , 136, 46-47	2.2	
151	Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China. <i>Blood</i> , <b>2020</b> , 136, 39-40	2.2	0
150	Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies. <i>Blood</i> , <b>2020</b> , 136, 43-43	2.2	2
149	Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , <b>2020</b> , 136, 1-1	2.2	4
148	First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3026-3026	2.2	7
147	ORP8 induces apoptosis by releasing cytochrome c from mitochondria in non-small cell lung cancer. <i>Oncology Reports</i> , <b>2020</b> , 43, 1516-1524	3.5	2
146	Selection of new immunotherapy targets for NK/T cell lymphoma. <i>American Journal of Translational Research (discontinued)</i> , <b>2020</b> , 12, 7034-7047	3	4
145	Primary Causes of Death in Patients with Non-Hodgkin's Lymphoma: A Retrospective Cohort Study. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 3155-3162	3.6	1
144	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. <i>Immunotherapy</i> , <b>2020</b> , 12, 681-696	3.8	4
143	Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8033-8033	2.2	
142	Outcomes of GDPT (gemcitabine, cisplatin, prednisone,thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8018-8018	2.2	
141	sATP-binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T-cell lymphoma side population cells. <i>Oncology Reports</i> , <b>2020</b> , 44, 1467-1478	3.5	
140	Potential strategies against resistance to CAR T-cell therapy in haematological malignancies. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920962963	5.4	5
139	Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. <i>European Journal of Radiology</i> , <b>2020</b> , 133, 109301	4.7	4
138	Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. <i>Clinical Epigenetics</i> , <b>2020</b> , 12, 169	7.7	6
137	Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases. <i>OncoTargets and Therapy</i> , <b>2020</b> , 13, 7189-7197	4.4	7

136	Targeting PD-L1 in non-small cell lung cancer using CAR T cells. <i>Oncogenesis</i> , <b>2020</b> , 9, 72	6.6	17
135	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 38	22.4	7
134	High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 1903-1912	3.6	7
133	High level of lncRNA H19 expression is associated with shorter survival in esophageal squamous cell cancer patients. <i>Pathology Research and Practice</i> , <b>2019</b> , 215, 152638	3.4	12
132	Prognostic nomogram for overall survival in upper aerodigestive tract extranodal natural killer/T-cell lymphoma, nasal type, stages IE and IIE: A SEER-based study. <i>Oncology Letters</i> , <b>2019</b> , 18, 3493-3500 <sup>2</sup>	3.6	2
131	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , <b>2019</b> , 9, 33-43	2.6	3
130	Soluble fms-like tyrosine kinase-1-enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1962-1972	3.2	7
129	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. <i>Nature Communications</i> , <b>2019</b> , 10, 4209	17.4	16
128	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , <b>2019</b> , 32, 741-754	9.8	20
127	Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells. <i>Cancer Medicine</i> , <b>2019</b> , 8, 3892-3904	4.8	17
126	Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 3555-3564	3.6	9
125	Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma. <i>Hematology</i> , <b>2019</b> , 24, 440-445	2.2	6
124	Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: A cohort study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0214860	3.7	4
123	Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with , gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 1363-1372	3.6	6
122	c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. <i>Journal of Cellular Biochemistry</i> , <b>2019</b> , 120, 12628-12637	4.7	26
121	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , <b>2019</b> , 11, 515-529	3.8	12
120	Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma. <i>Oncologist</i> , <b>2019</b> , 24, e1123-e1131	5.7	16
119	Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN- $\gamma$ -associated JAK-STAT pathway. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 2079-2088	4.4	16



118	The clinical features and prognosis of 100 AIDS-related lymphoma cases. <i>Scientific Reports</i> , <b>2019</b> , 9, 53814.9	6
117	Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. <i>Oncology Letters</i> , <b>2019</b> , 18, 161-168	2.6 0
116	Non-coding RNAs in Natural Killer/T-Cell Lymphoma. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 515	5.3 12
115	Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 8277-8284	3.6
114	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. <i>Nature Communications</i> , <b>2019</b> , 10, 5061	17.4 9
113	Low Expression of 14-3-3beta Is Associated With Adverse Survival of Diffuse Large B-Cell Lymphoma Patients. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 237	4.9
112	Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , <b>2019</b> , 134, 755-755	2.2 12
111	Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labeled Study with Ddgp Regimen Versus SMILE Regimen. <i>Blood</i> , <b>2019</b> , 134, 463-463	2.2 7
110	Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 5221-5221	2.2 1
109	GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary result of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e14072-e14072	2.2 2
108	Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China. <i>International Journal of Ophthalmology</i> , <b>2019</b> , 12, 1731-1736	1.4 3
107	Anti-senescence role of heterozygous fumarate hydratase gene knockout in rat lung fibroblasts. <i>Aging</i> , <b>2019</b> , 11, 573-589	5.6 3
106	B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma. <i>Aging</i> , <b>2019</b> , 11, 3939-3957	5.6 4
105	Role of circular RNA in hematological malignancies. <i>Oncology Letters</i> , <b>2019</b> , 18, 4385-4392	2.6 8
104	Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.. <i>Translational Cancer Research</i> , <b>2019</b> , 8, 2485-2495	0.3 1
103	Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 2851-2851	2.2
102	Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study. <i>Blood</i> , <b>2019</b> , 134, 2873-2873	2.2
101	Latent Membrane Protein 1 Contributes to Deficient Cellular Immunity in NKTCL Patients. <i>Blood</i> , <b>2019</b> , 134, 3969-3969	2.2

100	Circular METRN RNA hsa_circ_0037251 Promotes Glioma Progression by Sponging miR-1229-3p and Regulating mTOR Expression. <i>Scientific Reports</i> , <b>2019</b> , 9, 19791	4.9	20
99	CircCDYL Serves as a New Biomarker in Mantle Cell Lymphoma and Promotes Cell Proliferation. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 10215-10221	3.6	16
98	miR-150 might inhibit cell proliferation and promote cell apoptosis by targeting LMO4 in Burkitt lymphoma. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 9652-9662	7	8
97	Recurrent PDGFRB mutations in unicentric Castleman disease. <i>Leukemia</i> , <b>2019</b> , 33, 1035-1038	10.7	21
96	One method to establish Epstein-Barr virus-associated NK/T cell lymphoma mouse models. <i>Journal of Cellular and Molecular Medicine</i> , <b>2019</b> , 23, 1509-1516	5.6	3
95	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. <i>Cancer Biology and Therapy</i> , <b>2019</b> , 20, 31-41	4.6	23
94	FOXC1 silencing inhibits the epithelial-to-mesenchymal transition of glioma cells: Involvement of E-catenin signaling. <i>Molecular Medicine Reports</i> , <b>2019</b> , 19, 251-261	2.9	8
93	Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , <b>2018</b> , 15, 8034-8038	2.6	1
92	Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngsters. <i>Scientific Reports</i> , <b>2018</b> , 8, 1088	4.9	8
91	SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. <i>Experimental Cell Research</i> , <b>2018</b> , 364, 125-132	4.2	13
90	Effect of Concomitant Positive Hepatitis B Surface Antigen on the Risk of Liver Metastasis: A Retrospective Clinical Study of 4033 Consecutive Cases of Newly Diagnosed Colorectal Cancer. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1948-1952	11.6	9
89	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 58	22.4	55
88	L265P Mutation in Lymphoid Malignancies. <i>Cancer Research</i> , <b>2018</b> , 78, 2457-2462	10.1	52
87	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. <i>Oncogene</i> , <b>2018</b> , 37, 3151-3165	9.2	64
86	miR-455-3p serves as prognostic factor and regulates the proliferation and migration of non-small cell lung cancer through targeting HOXB5. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 495, 1074-1080	3.4	34
85	Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 406-410	4.5	17
84	Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. <i>Oncology Letters</i> , <b>2018</b> , 16, 1275-1284	2.6	15
83	High SRPX2 protein expression predicts unfavorable clinical outcome in patients with prostate cancer. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 3149-3157	4.4	6



82	Dual TGF- $\beta$ and PD-1 blockade synergistically enhances MAGE-A3-specific CD8 T cell response in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2561-2574	7.5	49
81	Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 1265-1277	4.9	2
80	TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/ $\beta$ -catenin pathway. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 7	8.5	14
79	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 15	22.4	93
78	Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat diet.. <i>RSC Advances</i> , <b>2018</b> , 8, 16636-16644	3.7	2
77	IL-13 and IL-13R $\alpha$ are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 503, 2715-2720	3.4	2
76	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 140, 427-434	4.8	12
75	Gelsolin regulates proliferation, apoptosis and invasion in natural killer/T-cell lymphoma cells. <i>Biology Open</i> , <b>2018</b> , 7,	2.2	2
74	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Oncotarget</i> , <b>2018</b> , 9, 16213-16219	3.3	6
73	A proposal for a new staging system for extranodal natural killer T-cell lymphoma, nasal type, to predict the treatment strategy: A multicentre study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7552-7552	2.2	
72	Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. <i>Chinese Medical Journal</i> , <b>2018</b> , 131, 1767-1775	2.9	2
71	MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. <i>Anti-Cancer Drugs</i> , <b>2018</b> , 29, 861-870	2.4	7
70	Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review. <i>Oncology Letters</i> , <b>2018</b> , 16, 6624-6632	2.6	3
69	Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. <i>Cancer Cell International</i> , <b>2018</b> , 18, 150	6.4	3
68	IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4. <i>BioMed Research International</i> , <b>2018</b> , 2018, 2606834	3	2
67	Clinicopathological analysis of the hydroa vacciniforme-like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T-cell lymphoma. <i>Experimental and Therapeutic Medicine</i> , <b>2018</b> , 16, 4772-4778	2.1	1
66	AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. <i>Molecular Medicine</i> , <b>2018</b> , 24, 35	6.2	14
65	Platelet-derived growth factor receptor alpha (PDGFR $\alpha$ ) is overexpressed in NK/T-cell lymphoma and mediates cell survival. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 504, 525-531	3.4	7

64	B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 12907	4.9	5
63	Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy. <i>Anti-Cancer Drugs</i> , <b>2018</b> , 29, 637-645	2.4	11
62	Bushenshugan Formula Attenuates the Development of Lung Cancer by Inhibiting Epithelial-Mesenchymal Transition. <i>Cellular Physiology and Biochemistry</i> , <b>2018</b> , 47, 1977-1988	3.9	8
61	Long Noncoding RNA PlncRNA-1 Promotes Colorectal Cancer Cell Progression by Regulating the PI3K/Akt Signaling Pathway. <i>Oncology Research</i> , <b>2018</b> , 26, 261-268	4.8	39
60	Utility of baseline, interim and end-of-treatment F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase. <i>Scientific Reports</i> , <b>2017</b> , 7, 41057	4.9	16
59	Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma. <i>Oncology Letters</i> , <b>2017</b> , 13, 1211-1215	2.6	9
58	Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. <i>Scientific Reports</i> , <b>2017</b> , 7, 682	4.9	16
57	The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 772-780	4.5	20
56	Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. <i>International Journal of Hematology</i> , <b>2017</b> , 106, 612-621	2.3	8
55	Pretreatment 14-3-3 epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginase-based chemotherapy. <i>Proteomics - Clinical Applications</i> , <b>2017</b> , 11, 1600111	3.1	8
54	RING box protein-1 gene involved in flagellar disassembly of <i>Dunaliella salina</i> . <i>Folia Microbiologica</i> , <b>2017</b> , 62, 57-62	2.8	
53	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1597	8.4	145
52	Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. <i>Oncotarget</i> , <b>2017</b> , 8, 7201-7207	3.3	23
51	Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas. <i>Oncotarget</i> , <b>2017</b> , 8, 1058-1073	3.3	31
50	A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway. <i>Oncotarget</i> , <b>2017</b> , 8, 10954-10965	3.3	9
49	Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers. <i>Oncotarget</i> , <b>2017</b> , 8, 13344-13356	3.3	16
48	Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells. <i>Oncotarget</i> , <b>2017</b> , 8, 46363-46380	3.3	37
47	Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. <i>Oncotarget</i> , <b>2017</b> , 8, 72182-72196	3.3	31

46	S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine. <i>Scientific Reports</i> , <b>2016</b> , 6, 23695	4.9	14
45	MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer. <i>BMC Cancer</i> , <b>2016</b> , 16, 894	4.8	24
44	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 21	22.4	140
43	Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. <i>Oncology Letters</i> , <b>2016</b> , 11, 693-698	2.6	10
42	RelA NF- $\kappa$ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , <b>2016</b> , 8, 3321-3340	5.6	20
41	Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149. <i>Oncotarget</i> , <b>2016</b> , 7, 55721-55731	3.3	15
40	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. <i>Oncotarget</i> , <b>2016</b> , 7, 53808-53819	3.3	17
39	Generation of TALEN-mediated FH knockout rat model. <i>Oncotarget</i> , <b>2016</b> , 7, 61656-61669	3.3	12
38	Establishment of mitochondrial pyruvate carrier 1 (MPC1) gene knockout mice with preliminary gene function analyses. <i>Oncotarget</i> , <b>2016</b> , 7, 79981-79994	3.3	15
37	Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma. <i>American Journal of Cancer Research</i> , <b>2016</b> , 6, 2076-2087	4.4	3
36	GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975). <i>Blood</i> , <b>2016</b> , 128, 2989-2989	2.2	
35	The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>Oncotarget</i> , <b>2016</b> , 7, 58396-58404	3.3	12
34	Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. <i>BMC Cancer</i> , <b>2016</b> , 16, 537	4.8	6
33	PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence. <i>Oncotarget</i> , <b>2016</b> , 7, 53837-53852	3.3	15
32	Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia. <i>Oncology Letters</i> , <b>2016</b> , 12, 4173-4180	2.6	10
31	Long-term remission of subcutaneous panniculitis-like T-cell lymphoma with central nervous system involvement: A case report. <i>Oncology Letters</i> , <b>2016</b> , 12, 611-614	2.6	3
30	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5223-5228	12.9	72
29	ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity. <i>Oncology Reports</i> , <b>2016</b> , 35, 2785-94	3.5	11

28	Aldehyde Dehydrogenase-1 Expression Predicts Unfavorable Outcomes in Patients with Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , <b>2016</b> , 36, 343-9	2.3	6
27	TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2015</b> , 463, 638-43	3.4	33
26	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 96	22.4	62
25	Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2613-8	1.9	7
24	ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target. <i>Leukemia Research</i> , <b>2015</b> , 39, 1448-54	2.7	13
23	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 104	22.4	95
22	Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature. <i>Oncology Letters</i> , <b>2015</b> , 10, 3261-3265	2.6	5
21	Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. <i>Oncotarget</i> , <b>2015</b> , 6, 37758-69	3.3	38
20	Inhibition of cell proliferation and metastasis of human hepatocellular carcinoma by miR-137 is regulated by CDC42. <i>Oncology Reports</i> , <b>2015</b> , 34, 2523-32	3.5	15
19	Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis. <i>International Journal of Molecular Medicine</i> , <b>2015</b> , 36, 1335-44	4.4	17
18	Six1 promotes glioblastoma cell proliferation and invasion by upregulation of connective tissue growth factor. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 1823-30	4.4	10
17	Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2015</b> , 8, 14875-84	1.4	17
16	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 23157-80	3.3	32
15	ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro. <i>Oncotarget</i> , <b>2015</b> , 6, 42687-703	3.3	16
14	Decreased Expression of PDHE1 Predicts Worse Clinical Outcome in Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , <b>2015</b> , 35, 5533-8	2.3	10
13	Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. <i>Oncology Letters</i> , <b>2014</b> , 8, 1461-1469	2.6	36
12	Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report. <i>Oncology Letters</i> , <b>2014</b> , 8, 886-890	2.6	2
11	A retrospective study of external beam radiation, neutron brachytherapy, and concurrent chemotherapy for patients with localized advanced carcinoma of the esophagus. <i>Radiation Oncology</i> , <b>2014</b> , 9, 294	4.2	2

10	Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma. <i>Oncology Reports</i> , <b>2014</b> , 32, 853-9	3.5	11
9	miRNA-155 modulates the malignant biological characteristics of NK/T-cell lymphoma cells by targeting FOXO3a gene. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , <b>2014</b> , 34, 882-888		14
8	Peroxiredoxin 1 is involved in disassembly of flagella and cilia. <i>Biochemical and Biophysical Research Communications</i> , <b>2014</b> , 444, 420-6	3.4	8
7	Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2014</b> , 7, 631-9	1.4	15
6	Cancer stem cells as a potential therapeutic target in breast cancer. <i>Stem Cell Investigation</i> , <b>2014</b> , 1, 14	5.1	6
5	A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 5475-5475		2.2
4	a Proposal for a New Staging System of Extranodal Natural Killer T-cell Lymphoma, Nasal-Type: a Multicenter Study of Chinese Southwest Oncology Group (CSWOG). <i>Blood</i> , <b>2014</b> , 124, 4444-4444	2.2	
3	The effects and mechanism of action of <i>Prunella vulgaris</i> l extract on Jurkat human T lymphoma cell proliferation. <i>Chinese-German Journal of Clinical Oncology</i> , <b>2009</b> , 8, 426-429		11
2	Humoral immunoreaction induced by TCR DNA vaccine for beta chain of T cell lymphoma. <i>Vaccine</i> , <b>2004</b> , 22, 2031-41	4.1	3
1	Short-Term effects of cinobufagin in the treatment of middle and advanced malignant tumors <b>1997</b> , 3, 120-122		